P2Y12 receptor inhibition with prasugrel and ticagrelor in STEMI patients after fibrinolytic therapy: Analysis from the SAMPA randomized trial

International Journal of Cardiology

Volumn 230, Issue , 2017, Pages 204-208

  Guimarães, Leonardo de F C ^a   Généreux, Philippe ^b,c,d,e   Silveira, Diego ^a   Pesaro, Antonio Eduardo ^f   Falcão, Felipe ^a   Barbosa, Bruno Robalinho C ^a   de Souza, Cristiano Freitas ^a   Fonseca, Francisco A H ^a   Alves, Cláudia Maria Rodrigues ^a   Carvalho, Antônio Carlos de Camargo ^a   Stone, Gregg W ^b,c   Caixeta, Adriano ^a,f  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b CARDIOVASCULAR RESEARCH FOUNDATION   (United States)

^c Department of Orthopaedic Surgery   (United States)

^d HÔPITAL DU SACRÉ COEUR DE MONTRÉAL   (Canada)

^e MORRISTOWN MEDICAL CENTER   (United States)

^f HOSPITAL ISRAELITA ALBERT EINSTEIN   (Brazil)

Author keywords

Acute myocardial infarction; Fibrinolysis; Prasugrel; Ticagrelor

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; ENOXAPARIN; PRASUGREL; PURINERGIC P2Y12 RECEPTOR; TENECTEPLASE; TICAGRELOR; ADENOSINE; ANTITHROMBOCYTIC AGENT; PURINERGIC P2Y RECEPTOR ANTAGONIST;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ANGIOGRAPHY; FEMALE; FIBRINOLYSIS; FIBRINOLYTIC THERAPY; HUMAN; LOADING DRUG DOSE; MALE; PLATELET REACTIVITY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; THROMBOCYTE AGGREGATION; THROMBOCYTE AGGREGATION INHIBITION; ANALOGS AND DERIVATIVES; DOSE RESPONSE; FOLLOW UP; MIDDLE AGED; PROCEDURES; TIME FACTOR; TREATMENT OUTCOME;

ADENOSINE; CORONARY ANGIOGRAPHY; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; PRASUGREL HYDROCHLORIDE; PROSPECTIVE STUDIES; PURINERGIC P2Y RECEPTOR ANTAGONISTS; ST ELEVATION MYOCARDIAL INFARCTION; THROMBOLYTIC THERAPY; TIME FACTORS; TREATMENT OUTCOME;

EID: 85008462065     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2016.12.173     Document Type: Article

References (37)

1. [1] Hamm, C.W., Bassand, J.P., Agewall, S., et al. ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: the task force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur. Heart J. 32 (2011), 2999–3054.
2. [2] Jneid, H., Anderson, J.L., Wright, R.S., et al. 2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/non-ST-elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines. J. Am. Coll. Cardiol. 60 (2012), 645–681.
3. [3] Levine, G.N., Bates, E.R., Blankenship, J.C., et al. 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention. A report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines and the Society for Cardiovascular Angiography and Interventions. J. Am. Coll. Cardiol. 58 (2011), e44–122.
4. [4] Chen, Z.M., Jiang, L.X., Chen, Y.P., et al. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 366 (2005), 1607–1621.
5. [5] Sabatine, M.S., Cannon, C.P., Gibson, C.M., et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N. Engl. J. Med. 352 (2005), 1179–1189.
6. [6] Yusuf, S., Zhao, F., Mehta, S.R., et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N. Engl. J. Med. 345 (2001), 494–502.
7. [7] Hochholzer, W., Trenk, D., Frundi, D., et al. Time dependence of platelet inhibition after a 600-mg loading dose of clopidogrel in a large, unselected cohort of candidates for percutaneous coronary intervention. Circulation 111 (2005), 2560–2564.
8. [8] Serebruany, V.L., Steinhubl, S.R., Berger, P.B., Malinin, A.I., Bhatt, D.L., Topol, E.J., Variability in platelet responsiveness to clopidogrel among 544 individuals. J. Am. Coll. Cardiol. 45 (2005), 246–251.
9. [9] Snoep, J.D., Hovens, M.M., Eikenboom, J.C., van der Bom, J.G., Jukema, J.W., Huisman, M.V., Clopidogrel nonresponsiveness in patients undergoing percutaneous coronary intervention with stenting: a systematic review and meta-analysis. Am. Heart J. 154 (2007), 221–231.
10. [10] Wallentin, L., Becker, R.C., Budaj, A., et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med. 361 (2009), 1045–1057.
11. [11] Wiviott, S.D., Braunwald, E., McCabe, C.H., et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med. 357 (2007), 2001–2015.
12. [12] Alexopoulos, D., Perperis, A., Koniari, I., et al. Ticagrelor versus high dose clopidogrel in ST-segment elevation myocardial infarction patients with high platelet reactivity post fibrinolysis. J. Thromb. Thrombolysis 40 (2015), 261–267.
13. [13] Valenti, R., Marcucci, R., Comito, V., et al. Prasugrel in clopidogrel nonresponders undergoing percutaneous coronary intervention: the RECLOSE-3 study (REsponsiveness to CLOpidogrel and StEnt thrombosis). JACC Cardiovasc. Interv. 8 (2015), 1563–1570.
14. [14] Zeymer, U., Mateblowski, M., Neuhaus, K.L., Thrombin generation in patients with acute myocardial infarction treated with front-loaded rt-PA and recombinant Hirudin (HBW 023). J. Thromb. Thrombolysis 5 (1998), 203–207.
15. [15] Diego, A., de Prado, A.P., Cuellas, C., et al. P2Y12 platelet reactivity after thrombolytic therapy for ST-segment elevation myocardial infarction. Thromb. Res. 130 (2012), e31–e36.
16. [16] Mehran, R., Rao, S.V., Bhatt, D.L., et al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the bleeding academic research consortium. Circulation 123 (2011), 2736–2747.
17. [17] Stone, G.W., Witzenbichler, B., Weisz, G., et al. Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study. Lancet 382 (2013), 614–623.
18. [18] Tantry, U.S., Bonello, L., Aradi, D., et al. Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding. J. Am. Coll. Cardiol. 62 (2013), 2261–2273.
19. [19] Alexopoulos, D., Xanthopoulou, I., Gkizas, V., et al. Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction. Circ. Cardiovasc. Interv 5 (2012), 797–804.
20. [20] Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC), Steg, P.G., James, S.K., et al. ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur. Heart J. 33 (2012), 2569–2619.
21. [21] O'Gara, P.T., Kushner, F.G., Ascheim, D.D., et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines. Circulation 127 (2013), 529–555.
22. [22] Giugliano, R.P., Braunwald, E., The year in non-ST-segment elevation acute coronary syndromes. J. Am. Coll. Cardiol. 46 (2005), 906–919.
23. [23] Gurbel, P.A., Serebruany, V.L., Shustov, A.R., et al. Effects of reteplase and alteplase on platelet aggregation and major receptor expression during the first 24 hours of acute myocardial infarction treatment. GUSTO-III investigators. Global use of strategies to open occluded coronary arteries. J. Am. Coll. Cardiol. 31 (1998), 1466–1473.
24. [24] Moser, M., Nordt, T., Peter, K., et al. Platelet function during and after thrombolytic therapy for acute myocardial infarction with reteplase, alteplase, or streptokinase. Circulation 100 (1999), 1858–1864.
25. [25] Rasmanis, G., Vesterqvist, O., Green, K., Edhag, O., Henriksson, P., Evidence of increased platelet activation after thrombolysis in patients with acute myocardial infarction. Br. Heart J. 68 (1992), 374–376.
26. [26] Alexopoulos, D., P2Y12 inhibitors adjunctive to primary PCI therapy in STEMI: fighting against the activated platelets. Int. J. Cardiol. 163 (2013), 249–255.
27. [27] Parodi, G., Valenti, R., Bellandi, B., et al. Comparison of prasugrel and ticagrelor loading doses in ST-segment elevation myocardial infarction patients: RAPID (rapid activity of platelet inhibitor drugs) primary PCI study. J. Am. Coll. Cardiol. 61 (2013), 1601–1606.
28. [28] Franchi, F., Rollini, F., Cho, J.R., et al. Impact of escalating loading dose regimens of ticagrelor in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: results of a prospective randomized pharmacokinetic and pharmacodynamic investigation. JACC Cardiovasc. Interv. 8 (2015), 1457–1467.
29. [29] Rollini, F., Franchi, F., Hu, J., et al. Crushed prasugrel tablets in patients with STEMI undergoing primary percutaneous coronary intervention: the CRUSH study. J. Am. Coll. Cardiol. 67 (2016), 1994–2004.
30. [30] Rollini, F., Franchi, F., Cho, J.R., et al. A head-to-head pharmacodynamic comparison of prasugrel vs. ticagrelor after switching from clopidogrel in patients with coronary artery disease: results of a prospective randomized study. Eur. Heart J. 37 (2016), 2722–2730.
31. [31] Gurbel, P.A., Bliden, K.P., Butler, K., et al. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study. Circulation 120 (2009), 2577–2585.
32. [32] Wallentin, L., Varenhorst, C., James, S., et al. Prasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease. Eur. Heart J. 29 (2008), 21–30.
33. [33] Rollini, F., Franchi, F., Angiolillo, D.J., Switching P2Y12-receptor inhibitors in patients with coronary artery disease. Nat. Rev. Cardiol. 13 (2016), 11–27.
34. [34] Authors/Task Force m, Windecker, S., Kolh, P., et al. 2014 ESC/EACTS guidelines on myocardial revascularization: the task force on myocardial revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur. Heart J. 35 (2014), 2541–2619.
35. [35] Campo, G., Parrinello, G., Ferraresi, P., et al. Prospective evaluation of on-clopidogrel platelet reactivity over time in patients treated with percutaneous coronary intervention relationship with gene polymorphisms and clinical outcome. J. Am. Coll. Cardiol. 57 (2011), 2474–2483.
36. [36] Mayer, K., Schulz, S., Bernlochner, I., et al. A comparative cohort study on personalised antiplatelet therapy in PCI-treated patients with high on-clopidogrel platelet reactivity. Results of the ISAR-HPR registry. Thromb. Haemost. 112 (2014), 342–351.
37. [37] Flechtenmacher, N., Kammerer, F., Dittmer, R., et al. Clopidogrel resistance in neurovascular stenting: correlations between light transmission aggregometry, VerifyNow, and the Multiplate. AJNR Am. J. Neuroradiol. 36 (2015), 1953–1958.